[
  {
    "ts": null,
    "headline": "Why Kenvue Stock Tumbled by 13% on Thursday",
    "summary": "The company's baby powder product is under legal fire once again.",
    "url": "https://finnhub.io/api/news?id=2a7e11f1deae4132a68947359a8049e7453680ec96df5afac7b9d26c693821ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760652366,
      "headline": "Why Kenvue Stock Tumbled by 13% on Thursday",
      "id": 137121743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The company's baby powder product is under legal fire once again.",
      "url": "https://finnhub.io/api/news?id=2a7e11f1deae4132a68947359a8049e7453680ec96df5afac7b9d26c693821ae"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue Stock Falls 13% in Its Worst Day on Record",
    "summary": "Shares of Kenvue fell 13% Thursday to $14.11, its lowest finish since the consumer healthcare firm spun off from Johnson & Johnson in 2023.  The decline was the sharpest on record for Kenvue, according to Dow Jones Market Data.  The fall surpassed the day last month that President Trump warned that the active ingredient in Kenvue's Tylenol is a potential cause of autism.",
    "url": "https://finnhub.io/api/news?id=8945c5a816dff53ae95452e6b4b693a8e6a11760c32b8fec2757327a6b489c9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760647810,
      "headline": "Kenvue Stock Falls 13% in Its Worst Day on Record",
      "id": 137121744,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Shares of Kenvue fell 13% Thursday to $14.11, its lowest finish since the consumer healthcare firm spun off from Johnson & Johnson in 2023.  The decline was the sharpest on record for Kenvue, according to Dow Jones Market Data.  The fall surpassed the day last month that President Trump warned that the active ingredient in Kenvue's Tylenol is a potential cause of autism.",
      "url": "https://finnhub.io/api/news?id=8945c5a816dff53ae95452e6b4b693a8e6a11760c32b8fec2757327a6b489c9e"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: TSMC profit surges, CSX and Interactive Brokers Q3 results beat estimates",
    "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=7fa7cc50a2fa24b7712fd58e77c4f665c22d8c05607d82776b7eeec8312045b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760647356,
      "headline": "Earnings live: TSMC profit surges, CSX and Interactive Brokers Q3 results beat estimates",
      "id": 137120808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=7fa7cc50a2fa24b7712fd58e77c4f665c22d8c05607d82776b7eeec8312045b2"
    }
  },
  {
    "ts": null,
    "headline": "Jury Orders Johnson & Johnson (JNJ) to Pay $966M in Talc Verdict",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of Ray Dalio’s latest top stock positions. On October 7, a Los Angeles jury ordered Johnson & Johnson (NYSE:JNJ) to pay $966 million to the family of a California woman who died from mesothelioma. This was after the jury found the company’s talc-based baby powder caused the woman’s cancer. […]",
    "url": "https://finnhub.io/api/news?id=b5437b075f151f4da9bbd039640983de42f47b313bdcaea70a7d63cfde30eb53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760645982,
      "headline": "Jury Orders Johnson & Johnson (JNJ) to Pay $966M in Talc Verdict",
      "id": 137121746,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of Ray Dalio’s latest top stock positions. On October 7, a Los Angeles jury ordered Johnson & Johnson (NYSE:JNJ) to pay $966 million to the family of a California woman who died from mesothelioma. This was after the jury found the company’s talc-based baby powder caused the woman’s cancer. […]",
      "url": "https://finnhub.io/api/news?id=b5437b075f151f4da9bbd039640983de42f47b313bdcaea70a7d63cfde30eb53"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson’s (JNJ) Stock Is Now Positioned To “Challenge Eli Lilly,” Says Jim Cramer",
    "summary": "We recently published Jim Cramer Talked About These 8 Stocks & The Quantum Computing Dip. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) announced yesterday that it would spin off its orthopedics business to allow it to become the largest firm of its kind in the […]",
    "url": "https://finnhub.io/api/news?id=01ca43712277f5673183febd5d5540dda998468a717c506ecc8f8a8d574c70c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760643448,
      "headline": "Johnson & Johnson’s (JNJ) Stock Is Now Positioned To “Challenge Eli Lilly,” Says Jim Cramer",
      "id": 137121702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published Jim Cramer Talked About These 8 Stocks & The Quantum Computing Dip. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) announced yesterday that it would spin off its orthopedics business to allow it to become the largest firm of its kind in the […]",
      "url": "https://finnhub.io/api/news?id=01ca43712277f5673183febd5d5540dda998468a717c506ecc8f8a8d574c70c8"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue Stock Tumbles on a New Challenge. It Isn’t Tylenol This Time.",
    "summary": "More than 3,000 people filed suit in the U.K. against a Kenvue subsidiary and Johnson & Johnson over baby powder.",
    "url": "https://finnhub.io/api/news?id=b1cf6024961dc4c4622dbe03bbe866038f0fde491a2fc3cc25b54e987f4c45ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760639940,
      "headline": "Kenvue Stock Tumbles on a New Challenge. It Isn’t Tylenol This Time.",
      "id": 137121748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "More than 3,000 people filed suit in the U.K. against a Kenvue subsidiary and Johnson & Johnson over baby powder.",
      "url": "https://finnhub.io/api/news?id=b1cf6024961dc4c4622dbe03bbe866038f0fde491a2fc3cc25b54e987f4c45ef"
    }
  },
  {
    "ts": null,
    "headline": "Halozyme Rallies Almost 40% YTD: How Should You Play the Stock?",
    "summary": "HALO's nearly 40% YTD surge is fueled by higher ENHANZE royalties. The Elektrofi deal also positions the company for long-term diversification.",
    "url": "https://finnhub.io/api/news?id=69461a1d405517fc2fe654566c08ed38b694f63ef6a478025db584fb9e754f51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760637060,
      "headline": "Halozyme Rallies Almost 40% YTD: How Should You Play the Stock?",
      "id": 137121749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "HALO's nearly 40% YTD surge is fueled by higher ENHANZE royalties. The Elektrofi deal also positions the company for long-term diversification.",
      "url": "https://finnhub.io/api/news?id=69461a1d405517fc2fe654566c08ed38b694f63ef6a478025db584fb9e754f51"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue stock falls as UK talc lawsuits raise liability concerns",
    "summary": "Investing.com -- Kenvue (NYSE:KVUE) stock fell 5% Thursday as the consumer health company faces new legal challenges in the United Kingdom related to allegations that its talc products cause cancer.",
    "url": "https://finnhub.io/api/news?id=28f4e65e12f860e9f06a1fd4a4b55f5dee9143a2f7e83e292fb424f2f914f439",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760634297,
      "headline": "Kenvue stock falls as UK talc lawsuits raise liability concerns",
      "id": 137121750,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investing.com -- Kenvue (NYSE:KVUE) stock fell 5% Thursday as the consumer health company faces new legal challenges in the United Kingdom related to allegations that its talc products cause cancer.",
      "url": "https://finnhub.io/api/news?id=28f4e65e12f860e9f06a1fd4a4b55f5dee9143a2f7e83e292fb424f2f914f439"
    }
  },
  {
    "ts": null,
    "headline": "J&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan",
    "summary": "J&J's surprise plan to spin off its Orthopaedics unit as DePuy Synthes is aimed at sharpening MedTech focus and boosting growth margins.",
    "url": "https://finnhub.io/api/news?id=3a541310f823df07be91be8a3299325cec958b317fa9413f90e9cbe8509e4d41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760634120,
      "headline": "J&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan",
      "id": 137121751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J's surprise plan to spin off its Orthopaedics unit as DePuy Synthes is aimed at sharpening MedTech focus and boosting growth margins.",
      "url": "https://finnhub.io/api/news?id=3a541310f823df07be91be8a3299325cec958b317fa9413f90e9cbe8509e4d41"
    }
  },
  {
    "ts": null,
    "headline": "Exclusive: Ulta Beauty’s new CFO is a Johnson & Johnson veteran tasked to help lead the company’s next chapter",
    "summary": "Christopher DelOrefice will join the company on Dec. 5.",
    "url": "https://finnhub.io/api/news?id=eba71d50dd0efc14d8191703b338351953d298c99013c41e3fa003a4faaade8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760619600,
      "headline": "Exclusive: Ulta Beauty’s new CFO is a Johnson & Johnson veteran tasked to help lead the company’s next chapter",
      "id": 137106195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Christopher DelOrefice will join the company on Dec. 5.",
      "url": "https://finnhub.io/api/news?id=eba71d50dd0efc14d8191703b338351953d298c99013c41e3fa003a4faaade8b"
    }
  },
  {
    "ts": null,
    "headline": "Ulta Beauty Names Christopher DelOrefice as Chief Financial Officer",
    "summary": "BOLINGBROOK, Ill., October 16, 2025--Ulta Beauty Names Christopher DelOrefice as Chief Financial Officer",
    "url": "https://finnhub.io/api/news?id=29aff19e3a7c2e7da29763270423a552c4e69298abf065d64911a6ac8f3f2756",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760619600,
      "headline": "Ulta Beauty Names Christopher DelOrefice as Chief Financial Officer",
      "id": 137104443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BOLINGBROOK, Ill., October 16, 2025--Ulta Beauty Names Christopher DelOrefice as Chief Financial Officer",
      "url": "https://finnhub.io/api/news?id=29aff19e3a7c2e7da29763270423a552c4e69298abf065d64911a6ac8f3f2756"
    }
  },
  {
    "ts": null,
    "headline": "ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook",
    "summary": "JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.",
    "url": "https://finnhub.io/api/news?id=2a67e225a8694487302764befffa5108deab024de61300bcd7b8930caab888bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760619120,
      "headline": "ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook",
      "id": 137106196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.",
      "url": "https://finnhub.io/api/news?id=2a67e225a8694487302764befffa5108deab024de61300bcd7b8930caab888bb"
    }
  },
  {
    "ts": null,
    "headline": "Update: Johnson & Johnson Faces UK Lawsuit Over Talc Products",
    "summary": "(Updates with Johnson & Johnson's response in the fourth paragraph.) Johnson & Johnson (JNJ) is f",
    "url": "https://finnhub.io/api/news?id=e64f196e5b819790c767a79ca19e079101371df457c5ab7095c76658b8701df1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760617602,
      "headline": "Update: Johnson & Johnson Faces UK Lawsuit Over Talc Products",
      "id": 137104444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "(Updates with Johnson & Johnson's response in the fourth paragraph.) Johnson & Johnson (JNJ) is f",
      "url": "https://finnhub.io/api/news?id=e64f196e5b819790c767a79ca19e079101371df457c5ab7095c76658b8701df1"
    }
  },
  {
    "ts": null,
    "headline": "TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care",
    "summary": "Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the efficacy and safety of TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) versus investigator's choice of DARZALEX FASPRO, pomalidomide, and dexamethasone (DPd) or DARZALEX FASPRO, bortezomib, and dexamethasone (DVd) in patients with relapsed/refract",
    "url": "https://finnhub.io/api/news?id=c36a9d82a97e8a53b210ee66df8a6542745bcb97559b9f6af5d62d3c2ab18d16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760616000,
      "headline": "TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care",
      "id": 137104445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the efficacy and safety of TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) versus investigator's choice of DARZALEX FASPRO, pomalidomide, and dexamethasone (DPd) or DARZALEX FASPRO, bortezomib, and dexamethasone (DVd) in patients with relapsed/refract",
      "url": "https://finnhub.io/api/news?id=c36a9d82a97e8a53b210ee66df8a6542745bcb97559b9f6af5d62d3c2ab18d16"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: TSMC profit surges amid 'strong' AI demand, Charles Schwab stock ticks higher, United slips",
    "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=9154a5d441e744ac2bad3d3ad0a49edf4048b5907d7375e0b559593567a6cc01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760615413,
      "headline": "Earnings live: TSMC profit surges amid 'strong' AI demand, Charles Schwab stock ticks higher, United slips",
      "id": 137104988,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=9154a5d441e744ac2bad3d3ad0a49edf4048b5907d7375e0b559593567a6cc01"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: TSMC profit surges amid 'strong' AI demand, Charles Schwab stock rises, United slips premarket",
    "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=2996fc78076758f9dd5561004ee2fd29fba0eafd2d44d521d446900c398a6d9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760615413,
      "headline": "Earnings live: TSMC profit surges amid 'strong' AI demand, Charles Schwab stock rises, United slips premarket",
      "id": 137104411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=2996fc78076758f9dd5561004ee2fd29fba0eafd2d44d521d446900c398a6d9b"
    }
  },
  {
    "ts": null,
    "headline": "Ulta appoints new CFO",
    "summary": "Christopher DelOrefice will take on the role in December, allowing interim CFO Chris Lialios to return to being senior vice president and controller.",
    "url": "https://finnhub.io/api/news?id=4b0d965b9bae444ce45da4fba223841e40359eb9a22b51dfff84d44aac8351f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760614560,
      "headline": "Ulta appoints new CFO",
      "id": 137106198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Christopher DelOrefice will take on the role in December, allowing interim CFO Chris Lialios to return to being senior vice president and controller.",
      "url": "https://finnhub.io/api/news?id=4b0d965b9bae444ce45da4fba223841e40359eb9a22b51dfff84d44aac8351f6"
    }
  },
  {
    "ts": null,
    "headline": "What J&J’s ortho spinoff means for the industry",
    "summary": "Analysts expect that DePuy Synthes could become a stronger competitor as a standalone company.",
    "url": "https://finnhub.io/api/news?id=495230cb946cc09bf9129b4fb23ca39714644d39c40fed150b70ffdf782c5da8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760613982,
      "headline": "What J&J’s ortho spinoff means for the industry",
      "id": 137121752,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Analysts expect that DePuy Synthes could become a stronger competitor as a standalone company.",
      "url": "https://finnhub.io/api/news?id=495230cb946cc09bf9129b4fb23ca39714644d39c40fed150b70ffdf782c5da8"
    }
  },
  {
    "ts": null,
    "headline": "BD CFO Chris DelOrefice leaving for new job",
    "summary": "Along with DelOrefice’s departure, BD reported preliminary fiscal fourth-quarter revenue that analysts said was below Wall Street consensus expectations.",
    "url": "https://finnhub.io/api/news?id=596fe0241ad100e6dc5b4b80fe90ca59ce735dee92f9d0c9ebce7d3fb06969e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760613343,
      "headline": "BD CFO Chris DelOrefice leaving for new job",
      "id": 137121753,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Along with DelOrefice’s departure, BD reported preliminary fiscal fourth-quarter revenue that analysts said was below Wall Street consensus expectations.",
      "url": "https://finnhub.io/api/news?id=596fe0241ad100e6dc5b4b80fe90ca59ce735dee92f9d0c9ebce7d3fb06969e6"
    }
  },
  {
    "ts": null,
    "headline": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.",
    "summary": "Investors should be able to count on these stocks to deliver steady and growing income over the long term.",
    "url": "https://finnhub.io/api/news?id=7e4800b5ba3d8b3036f1e4db47b26b94b80d7f16abe3b07b08340919642c68aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760611500,
      "headline": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.",
      "id": 137104447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investors should be able to count on these stocks to deliver steady and growing income over the long term.",
      "url": "https://finnhub.io/api/news?id=7e4800b5ba3d8b3036f1e4db47b26b94b80d7f16abe3b07b08340919642c68aa"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s orthopedics selloff keeps all eyes on a thriving pharma portfolio",
    "summary": "As another J&J department bites the dust, leadership is focused on what’s working in the pharma business, and there’s plenty to see.",
    "url": "https://finnhub.io/api/news?id=ffed7a576b6b22206d4a121f5959e08ccb702b170df32d607ab978ae3393accb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760599228,
      "headline": "J&J’s orthopedics selloff keeps all eyes on a thriving pharma portfolio",
      "id": 137104448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "As another J&J department bites the dust, leadership is focused on what’s working in the pharma business, and there’s plenty to see.",
      "url": "https://finnhub.io/api/news?id=ffed7a576b6b22206d4a121f5959e08ccb702b170df32d607ab978ae3393accb"
    }
  },
  {
    "ts": null,
    "headline": "J&J faces first UK lawsuits alleging its baby powder caused cancer",
    "summary": "STORY: Johnson & Johnson is facing its first lawsuits in the United Kingdom over alleged cancer-causing talc products.That comes as the drugmaker fights tens of thousands of similar claims in the United States.Legal firm KP Law said it filed a lawsuit Tuesday at the English High Court on behalf of 3,000 people who say their ovarian cancer or other diseases were caused by using J&J's baby powder between 1965 and 2023.The firm says J&J's talc products contained carcinogenic fibers, including asbestos which is often linked to mesothelioma, a deadly form of cancer.The value of the lawsuit against J&J and a subsidiary of its former consumer health unit Kenvue, is estimated at just over $1.3 billion.Kenvue said in a statement that J&J baby powder \"did not contain asbestos, and does not cause cancer\".J&J stopped selling talc-based baby powder in the U.S. in 2020, switching to a cornstarch product.It did the same in the UK in 2023.The company has sought to resolve the tens of thousands of similar lawsuits in the U.S. through bankruptcy.But federal courts rejected the strategy three times.",
    "url": "https://finnhub.io/api/news?id=372add6a6abaa663aa9b1fa0d144496552bbcdc9474a10e8b72b8571f216058d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760593594,
      "headline": "J&J faces first UK lawsuits alleging its baby powder caused cancer",
      "id": 137101921,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "STORY: Johnson & Johnson is facing its first lawsuits in the United Kingdom over alleged cancer-causing talc products.That comes as the drugmaker fights tens of thousands of similar claims in the United States.Legal firm KP Law said it filed a lawsuit Tuesday at the English High Court on behalf of 3,000 people who say their ovarian cancer or other diseases were caused by using J&J's baby powder between 1965 and 2023.The firm says J&J's talc products contained carcinogenic fibers, including asbestos which is often linked to mesothelioma, a deadly form of cancer.The value of the lawsuit against J&J and a subsidiary of its former consumer health unit Kenvue, is estimated at just over $1.3 billion.Kenvue said in a statement that J&J baby powder \"did not contain asbestos, and does not cause cancer\".J&J stopped selling talc-based baby powder in the U.S. in 2020, switching to a cornstarch product.It did the same in the UK in 2023.The company has sought to resolve the tens of thousands of similar lawsuits in the U.S. through bankruptcy.But federal courts rejected the strategy three times.",
      "url": "https://finnhub.io/api/news?id=372add6a6abaa663aa9b1fa0d144496552bbcdc9474a10e8b72b8571f216058d"
    }
  },
  {
    "ts": null,
    "headline": "J&J Announces Second Major Spinoff, Plans to Separate Orthopedics Division",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Johnson & Johnson (NYSE:JNJ) is an American multinational pharmaceutical, biotech, and medical technologies company. On Oc‍tober 14,​ the company⁠ announced that it will spin​ off i‌ts orthopedics division into a​ sepa‌rate company within the next 18 to 24 months. […]",
    "url": "https://finnhub.io/api/news?id=543f4cd603eb106f173e8e555753bf7c36bd65dae9f5b655187bf04481d21618",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760593589,
      "headline": "J&J Announces Second Major Spinoff, Plans to Separate Orthopedics Division",
      "id": 137101922,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Johnson & Johnson (NYSE:JNJ) is an American multinational pharmaceutical, biotech, and medical technologies company. On Oc‍tober 14,​ the company⁠ announced that it will spin​ off i‌ts orthopedics division into a​ sepa‌rate company within the next 18 to 24 months. […]",
      "url": "https://finnhub.io/api/news?id=543f4cd603eb106f173e8e555753bf7c36bd65dae9f5b655187bf04481d21618"
    }
  },
  {
    "ts": null,
    "headline": "The S&P 500’s Yield Is Weak. Consider These 3 Funds and 3 Stocks Instead.",
    "summary": "Many investors have significant exposure to the S&P 500 index and its paltry yield. Here’s how to bulk up the income portion of your portfolio.",
    "url": "https://finnhub.io/api/news?id=251f526d6f4b2efaf1492b1c5fa2350406ce545fc2e578eac5fd522b4d006054",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760592600,
      "headline": "The S&P 500’s Yield Is Weak. Consider These 3 Funds and 3 Stocks Instead.",
      "id": 137101799,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Many investors have significant exposure to the S&P 500 index and its paltry yield. Here’s how to bulk up the income portion of your portfolio.",
      "url": "https://finnhub.io/api/news?id=251f526d6f4b2efaf1492b1c5fa2350406ce545fc2e578eac5fd522b4d006054"
    }
  },
  {
    "ts": null,
    "headline": "Thousands sue Johnson & Johnson in UK over cancer claims",
    "summary": "Johnson & Johnson (J&J) is facing legal action from thousands of people in the UK who are accusing the global healthcare giant of knowingly selling talcum powder contaminated with asbestos.  More than 3,000 people allege they or a family member developed forms of ovarian cancer or mesothelioma from using Johnson's baby powder between 1965 and 2023.  A lawsuit has been filed by KP Law at the High Court in London seeking damages against J&J and Kenvue UK, which was split from the former in 2023 and now operates as a separate business.",
    "url": "https://finnhub.io/api/news?id=a5bf2e31594cc4b128eac6b1ec1d7086e159031d90925b03e3e9513fe83621ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760587260,
      "headline": "Thousands sue Johnson & Johnson in UK over cancer claims",
      "id": 137101925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (J&J) is facing legal action from thousands of people in the UK who are accusing the global healthcare giant of knowingly selling talcum powder contaminated with asbestos.  More than 3,000 people allege they or a family member developed forms of ovarian cancer or mesothelioma from using Johnson's baby powder between 1965 and 2023.  A lawsuit has been filed by KP Law at the High Court in London seeking damages against J&J and Kenvue UK, which was split from the former in 2023 and now operates as a separate business.",
      "url": "https://finnhub.io/api/news?id=a5bf2e31594cc4b128eac6b1ec1d7086e159031d90925b03e3e9513fe83621ac"
    }
  }
]